glioblastoma multiforme

Showing 2 posts of 2 posts found.

opdivo_1_1

BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme

September 5, 2019
Research and Development BMS, glioblastoma multiforme, opdivo, pharma

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the …

BMS blockbuster Opdivo falls short at Phase 3 in MGMT-unmethylated glioblastoma multiforme

May 10, 2019
Medical Communications, Research and Development BMS, Bristol-Myers Squibb, glioblastoma multiforme, pharma, trial failure

Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) has hit a hurdle, failing its primary endpoint in a Phase 3 trial investigating …

Latest content